Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STSP-0601 in Hemophilia With Inhibitors
NCT06922045Phase 3Active, not recruiting
- Sponsor
- Jiangsu BioJeTay Biotechnology
- Start
- Mar 2025
- Primary completion
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of bemiltenase alfa in hemophilia, sponsored by Jiangsu BioJeTay Biotechnology. Started Mar 2025; status: active, not recruiting.
02
Drugs
bemiltenase alfa
03
Conditions
hemophilia
Beyond the preview
Go deeper on NCT06922045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06922045.